Rimegepant for Treating Migraine Attacks
Author Information
Author(s): Dermitzakis Emmanouil V., Rikos Dimitrios, Vikelis Michail, Xiromerisiou Georgia, Zisopoulou Styliani, Rallis Dimitrios, Soldatos Panagiotis, Vlachos George S., Vasiliadis Georgios G., Argyriou Andreas A.
Primary Institution: Euromedica General Clinic, Thessaloniki, Greece
Hypothesis
The study aims to evaluate the efficacy and safety of rimegepant in treating migraine attacks.
Conclusion
Rimegepant is effective, safe, and well tolerated for treating acute migraine attacks.
Supporting Evidence
- Pain freedom at 2 hours was achieved in 32.1% of rimegepant intakes.
- Significant reductions in headache intensity were observed with a mean reduction of -4.8.
- Freedom from the most bothersome symptoms was achieved in 43% for photophobia, 53% for phonophobia, and 57% for nausea.
- 59% of instances allowed patients to return to everyday activities within 2 hours.
Takeaway
Rimegepant helps people with migraines feel better quickly and is safe to use.
Methodology
This was a multicenter, open-label pilot study where patients recorded their migraine symptoms before and after taking rimegepant.
Potential Biases
Potential bias due to the open-label design and lack of control group.
Limitations
The small sample size and open-label design limit the generalizability of the results.
Participant Demographics
Mean age of participants was 45.3 years, with 45 females and 9 males.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website